Pediatric sarcomas: Translating molecular pathogenesis of disease to novel therapeutic possibilities

Pediatric Research

Volumn 72, Issue 2, 2012, Pages 112-121

  Anderson, Jennifer L ^a   Denny, Christopher T ^a,b   Tap, William D ^c   Federman, Noah ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; ALISERTIB; AXITINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; CRIZOTINIB; DASATINIB; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; IMATINIB; IMC C 225; OBLIMERSEN; OLARATUMAB; PAZOPANIB; R 1507; SB 939; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TEPROTUMUMAB; TIVANTINIB; UNCLASSIFIED DRUG; VALPROIC ACID;

ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANGIOMATOID FIBROUS HISTIOCYTOMA; ANGIOSARCOMA; CARCINOGENESIS; CHILD; CHILDHOOD CANCER; CHONDROSARCOMA; CLEAR CELL SARCOMA; CONGENITAL FIBROSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; ENDOMETRIUM SARCOMA; EPITHELIOID SARCOMA; ES LIKE TUMOR; EWING SARCOMA; EXTRASKELETAL MYXOID CHONDROSARCOMA; FIBROSARCOMA; GASTROINTESTINAL TUMOR; GENE FUSION; GENE TARGETING; GENE TRANSLOCATION; GIANT CELL FIBROSARCOMA; HEMANGIOPERICYTOMA; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LOW GRADE FIBROMYXOID; LUNG ALVEOLUS CELL CARCINOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MESOBLASTIC NEPHROMA; METASTASIS; MYXOSARCOMA; NONRHABDOMYOSARCOMA SOFT TISSUE SARCOMA; OSTEOCLASTOMA; OSTEOSARCOMA; PEDIATRIC SARCOMA; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; RETROPERITONEAL SARCOMA; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

CHILD; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, FUSION; SARCOMA; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 84864349591     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.54     Document Type: Review

References (80)

1. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999:99-110.
2. Gurney JG, Young JL Jr, Roffers SD, Smith MA, Bunin GR. Soft tissue sarcomas. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999:111-24.
3. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11:184-92.
4. Rodriguez-Galindo C, Navid F, Khoury J, Krasin M. Ewing sarcoma family of tumors. In: Pappo A, ed. Pediatric Bone and Soft Tissue Sarcomas. Berlin/Heidelberg: Springer-Verlag, 2006:181-217.
5. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011;117:3027-32.
6. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-theart, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-8.
7. Pinto A, Dickman P, Parham D. Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma 2011;2011:856190.
8. Barr FG, Meyer WH. Role of fusion subtype in Ewing sarcoma. J Clin Oncol 2010;28:1973-4.
9. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNAbinding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
10. Kovar H. Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family. Sarcoma 2011;2011:837474.
11. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001;2:827-37. (Pubitemid 33674083)
12. Gangwal K, Sankar S, Hollenhorst PC, et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 2008;105:10149-54.
13. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000;275:24865-71. (Pubitemid 30626591)
14. Knoop LL, Baker SJ. EWS/FLI alters 5'-splice site selection. J Biol Chem 2001;276:22317-22.
15. France KA, Anderson JL, Park A, Denny CT. Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms. J Biol Chem 2011;286:22750-7.
16. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83. (Pubitemid 39014452)
17. Wakahara K, Ohno T, Kimura M, et al. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res 2008;6:1937-45.
18. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS ONE 2008;3:e2634.
19. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20:419-27.
20. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
21. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29:4541-7.
22. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29:4534-40.
23. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:256-62.
24. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
25. Toretsky JA, Erkizan V, Levenson A, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 2006;66:5574-81. (Pubitemid 43927107)
26. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009;15:750-6.
27. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 2011;170:e243-51.
28. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology, 6th edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011:923, 980-1.
29. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113-7. (Pubitemid 23079791)
30. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72. (Pubitemid 24187765)
31. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010;49:224-36.
32. Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, Kumar P. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008;12(6A):2281-94.
33. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008;27:2312-9. (Pubitemid 351501782)
34. Sorensen PHB, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20:2672-9. (Pubitemid 34575640)
35. Williamson D, Missiaglia E, de Reyni A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010;28:2151-8.
36. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998;58:3542-6. (Pubitemid 28376547)
37. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9.
38. Yan D, Dong Xda E, Chen X, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009;284:29596-604.
39. Hou J, Dong J, Sun L, et al. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med 2011;9:64.
40. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97. (Pubitemid 34257726)
41. Martins AS, Olmos D, Missiaglia E, Shipley J. Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011;2011:209736.
42. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999;96:13264-9.
43. Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 1998;18:4118-30. (Pubitemid 28287935)
44. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60.
45. Abraham J, Prajapati SI, Nishijo K, et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther 2011;10:697-707.
46. Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene 2010;29:6367-77.
47. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007;11:375-88. (Pubitemid 46518310)
48. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-8. (Pubitemid 24308337)
49. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14:2333-40.
50. de Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18) (p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet 1995;4:1097-9.
51. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999;91:974-5. (Pubitemid 29275883)
52. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008;466:2156-67.
53. Perani M, Ingram CJE, Cooper CS, Garrett MD, Goodwin GH. Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene 2003;22:8156-67. (Pubitemid 37487306)
54. Soulez M, Saurin AJ, Freemont PS, Knight JC. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 1999;18:2739-46. (Pubitemid 29237662)
55. Nagai M, Tanaka S, Tsuda M, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001;98:3843-8. (Pubitemid 32249859)
56. Takenaka S, Naka N, Araki N, et al. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol 2010;36:823-31.
57. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYTSSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-50. (Pubitemid 41185173)
58. Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000;9:1-8. (Pubitemid 30131955)
59. Allander SV, Illei PB, Chen Y, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161:1587-95. (Pubitemid 35265519)
60. de Bruijn DR, Allander SV, van Dijk AH, et al. The synovial-sarcoma- associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006;66:9474-82. (Pubitemid 44623645)
61. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006;25:1042-52. (Pubitemid 43277012)
62. Friedrichs N, K̈hler J, Endl E, et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008;216:428-39.
63. Krskov L, Kalinov M, Br̈ov H, Mrhalov M, Sumerauer D, Kodet R. Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma. Cancer Genet Cytogenet 2009;193:1-8.
64. Mancuso T, Mezzelani A, Riva C, et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 2000;80:805-13. (Pubitemid 30421798)
65. Albritton KH, Randall RL. Prospects for targeted therapy of synovial sarcoma. J Pediatr Hematol Oncol 2005;27:219-22. (Pubitemid 40604845)
66. Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res 2006;24:474-80. (Pubitemid 43778359)
67. Rheingold SR, Hogarty MD, Blaney SM, et al.; Children's Oncology Group Study. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007;25:1512-8. (Pubitemid 46733077)
68. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7. (Pubitemid 34310636)
69. Bozzi F, Ferrari A, Negri T, et al. Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Transl Oncol 2008;1:95-101.
70. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103:830-8. (Pubitemid 40216413)
71. Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008;13:467-73. (Pubitemid 351679928)
72. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007;56:968-73. (Pubitemid 46720204)
73. Dominguez-Malagon H, Valdez-Carrillo Mdel C, Cano-Valdez AM. Dermatofibroma and dermatofibrosarcoma protuberans: a comparative ultrastructural study. Ultrastruct Pathol 2006;30:283-91. (Pubitemid 44395490)
74. Iqbal CW, St Peter S, Ishitani MB. Pediatric dermatofibrosarcoma protuberans: multi-institutional outcomes. J Surg Res 2011;170:69-72.
75. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;15:95-8. (Pubitemid 27014958)
76. Simon MP, Navarro M, Roux D, Pouyssur J. Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene 2001;20:2965-75. (Pubitemid 33027764)
77. Giacchero D, Maire G, Nuin PA, et al. No correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans. J Invest Dermatol 2010;130:904-7.
78. Greco A, Fusetti L, Villa R, et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 1998;17:1313-9. (Pubitemid 28446172)
79. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growthinhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001;92:354-60. (Pubitemid 32249711)
80. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73. (Pubitemid 46224187)